For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes. Placebo | None | None | 0 | 8 | 4 | 8 | View |
| Ala-Cpn10 | Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range (0.16mg/kg \[10mg twice weekly\] to 5mg/kg \[300mg twice weekly\]) administered intravenously by infusion over 60 minutes. Ala-Cpn10 | None | None | 1 | 22 | 6 | 22 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Hypotension | None | Vascular disorders | MedDRA (Unspecified) | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Eye pain | None | Eye disorders | MedDRA (Unspecified) | View |
| diarrhoea | None | Gastrointestinal disorders | MedDRA (Unspecified) | View |
| dyspepsia | None | Gastrointestinal disorders | MedDRA (Unspecified) | View |
| Mouth ulceration | None | Gastrointestinal disorders | MedDRA (Unspecified) | View |
| Nausea | None | Gastrointestinal disorders | MedDRA (Unspecified) | View |
| Fatigue | None | General disorders | MedDRA (Unspecified) | View |
| cutaneous lupus erythematosus | None | Immune system disorders | MedDRA (Unspecified) | View |